HER2陽性早期乳がん (PHERGain) でのF-FDG-PETベースの病理学的完全応答に適応した戦略を用いた化学療法による3年間の侵襲性疾患フリー生存率:ランダム化,オープンラベル,フェーズ2試験

José Manuel Pérez-García1, Javier Cortés2, Manuel Ruiz-Borrego3

  • 1International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona 08022, Spain; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain.

PubMed
まとめ

トラストズマブとパーツズマブによるヒト表皮成長因子受容体2 (HER2) の二重阻害を用いた化学療法のない治療は,HER2陽性早期乳がん患者の3年間の侵襲性疾患フリー生存率を良好に示した. このPETに適応した戦略は,化学療法を行わずに済む患者を安全に特定しました.

関連する概念動画

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K